EUVIMEDEUVIMED entdecken
Open Access

Availability of Medications for Opioid Use Disorder in Opioid Treatment Programs

Zoe Lindenfeld, Jonathan H Cantor, Amanda I Mauri, Sachini Bandara, Aarya Suryavanshi, Noa Krawczyk

JAMA Network Open · 2025

DOI: 10.1001/jamanetworkopen.2025.17616 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA Network Open, 2025. Verfasst von Zoe Lindenfeld und 5 weiteren Autor:innen. Beteiligte Einrichtung: Edward J. Bloustein School of Planning and Public Policy, Rutgers University, New Brunswick, New Jersey. Hauptthemen laut MEDLINE: Opioid-Related Disorders, Opiate Substitution Treatment, Naltrexone, Methadone. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance As the primary facilities authorized to dispense methadone, opioid treatment programs (OTPs) are a critical access point for medications for opioid use disorder (MOUD). However, research is limited on the extent to which OTPs offer a broad range of MOUD and on the characteristics of programs that provide more comprehensive medication offerings.

Objective

To assess the percentage of US OTPs offering all 3 forms of MOUD (methadone, buprenorphine, and naltrexone) and compare organizational and county characteristics of OTPs with different MOUD service offerings. Design, Setting, and Participants This longitudinal cross-sectional study used data on a panel of OTPs listed in the annual National Directory of Drug and Alcohol Use Treatment Facilities from 2017 to 2023. Main Outcomes and Measures Measures included the percentage of OTPs offering buprenorphine, extended-release naltrexone, or all 3 MOUD from 2017 to 2023 (assuming all OTPs offered methadone). Descriptive statistics on organizational and county characteristics of OTPs by MOUD offerings were collected. Three longitudinal logistic regression models were used to estimate the odds of different MOUD offerings within OTPs, adjusting for organizational and county-level characteristics.

Results

This analysis included 10 298 facility-year observations, ranging from 1211 in 2017 to 1421 in 2023. From 2017 to 2023, the percentage of OTPs offering MOUD beyond methadone increased (buprenorphine: 811 [67.0%] in 2017 to 1209 [85.1%] in 2023; naltrexone: 463 [38.2%] in 2017 to 749 [52.7%] in 2023; all 3 MOUD: 402 [33.2%] in 2017 to 639 [45.0%] in 2023). OTPs offering all 3 MOUD (3985 [38.7%]) had significantly higher odds of accepting Medicare (adjusted odds ratio [AOR], 2.14; 95% CI, 1.67-2.74); offering peer services (AOR, 1.63; 95% CI, 1.25-2.12), mental health services (AOR, 2.07; 95% CI, 1.53-2.80), and telemedicine services (AOR, 1.53; 95% CI, 1.22-1.92); and being private nonprofit (AOR, 7.45; 95% CI, 4.67-11.87) or government operated (AOR, 41.83; 95% CI, 19.71-88.75) compared with private for profit.

Conclusions

In this cross-sectional study of OTPs, although the availability of MOUD beyond methadone increased over time, most OTPs still did not offer all 3 forms of MOUD as of 2023. Specific organizational characteristics, such as being government operated and accepting Medicare, were associated with more comprehensive MOUD offerings. Future research should evaluate why OTPs vary in their MOUD offerings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Opioid-Related DisordersOpiate Substitution TreatmentNaltrexoneMethadoneBuprenorphineNarcotic AntagonistsHealth Services AccessibilitySubstance Abuse Treatment CentersHumansCross-Sectional StudiesUnited StatesLongitudinal Studies

Substanzen

NaltrexoneMethadoneBuprenorphineNarcotic Antagonists

Autor:innen und Institutionen

  • Edward J. Bloustein School of Planning and Public Policy, Rutgers University, New Brunswick, New Jersey.
  • RAND, Santa Monica, California.
  • Department of Health Policy and Management, School of Public Health, University of Maryland, College Park.
  • Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
  • Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
  • Department of Population Health, NYU Grossman School of Medicine, New York, New York.

Zitieren

APA

Lindenfeld, Z., Cantor, J. H., Mauri, A. I., Bandara, S., Suryavanshi, A., & Krawczyk, N. (2025). Availability of Medications for Opioid Use Disorder in Opioid Treatment Programs. JAMA Network Open. https://doi.org/10.1001/jamanetworkopen.2025.17616

Vancouver

Lindenfeld Z, Cantor JH, Mauri AI, Bandara S, Suryavanshi A, Krawczyk N. Availability of Medications for Opioid Use Disorder in Opioid Treatment Programs. JAMA Network Open. 2025. doi:10.1001/jamanetworkopen.2025.17616

BibTeX
@article{Lindenfeld2025,
  author = {Lindenfeld, Zoe and Cantor, Jonathan H and Mauri, Amanda I and Bandara, Sachini and Suryavanshi, Aarya and Krawczyk, Noa},
  title = {Availability of Medications for Opioid Use Disorder in Opioid Treatment Programs},
  journal = {JAMA Network Open},
  year = {2025},
  doi = {10.1001/jamanetworkopen.2025.17616}
}
Kostenlos starten →